Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis

Scandinavian Journal of Urology

Volumn 49, Issue 3, 2015, Pages 230-236

  Lykke, Malene Risager ^a   Nielsen, Tommy Kjaergaard ^b   Ebbensgaard, Nanna Andersen ^b   Zieger, Karsten ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Aminolevulinic acid; Chemoprevention; Diagnostic use; Neoplasm recurrence; Prevention and control; Urinary bladder neoplasm

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; MITOMYCIN; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER SPASM; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTALGIA; CYSTECTOMY; CYSTOSCOPY; DYSURIA; FEMALE; FLUORESCENCE CYSTOSCOPY; HEALTH CARE COST; HEMATURIA; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC DIAGNOSIS; PHOTODYNAMICS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK REDUCTION; TRANSURETHRAL RESECTION OF THE BLADDER; TUMOR BIOPSY; URINE CYTOLOGY; FLUORESCENCE IMAGING; FOLLOW UP; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROCEDURES; RETROSPECTIVE STUDY; SURGERY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; URETHRA; URINARY BLADDER NEOPLASMS; UROLOGIC SURGERY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CHEMOPREVENTION; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; OPTICAL IMAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URETHRA; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 84929577669     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2015.1019562     Document Type: Article

References (22)

1. Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005;96:798-802.
2. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295-300.
3. Misop H, Schoenberg MP. The use of molecular diagnostics in bladder cancer. Urol Oncol 1999;5:87-92.
4. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30.
5. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-Analysis of published results of randomized clinical trials. J Urol 2004;171:2186-90, quiz 2435.
6. Urdaneta G, Solsona E, Palou J. Intravesical chemotherapy and BCG for the treatment of bladder cancer: evidence and opinion. Eur Urol Suppl 2008;7:542-7.
7. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;155:1233-8.
8. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30.
9. Babjuk M, Böhle A, Burger M, Comperat E, Kaasinen E, Palou J, et al. Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). European Association of Urology; 2014. Available from http://www.uroweb.org/gls/pdf/05%20Non-muscle% 20Invasive%20BC-TaT1-LR.pdf.
10. Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, et al. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int 2012;110:967-72.
11. Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008;179:101-5; discussion 105-6.
12. Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection The results of a prospective randomised multicentre study. Eur Urol 2009;55:773-80.
13. Oude Elferink P, Witjes JA. Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. Ther Adv Urol 2014;6:25-33.
14. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62-7.
15. Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58-62.
16. O'Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K. Prospective randomized trial of hexylaminolevulinate photodynamic-Assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 2013;112:1096-104.
17. Jichlinski P, Guillou L, Karlsen S. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer-A multicenter study. J Urol 2003;170: 226-9.
18. Josefsen LB, Boyle RW. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics 2012;2:916-66.
19. Malmstrom PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 2009;43:192-8.
20. Garfield SS, Gavaghan MB, Armstrong SO, Jones JS. The costeffectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol 2013;20:6682-9.
21. Marchetti A, Wang L, Magar R, Grossman HB, Lamm DL, Schellhammer PF, et al. Management of patients with bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther 2000;22:422-38.
22. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118: 1294-303.